ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. ExpreS2ion Biotech Holding AB's annualizedNet Income for the quarter that ended in Mar. 2026 was €-3.56 Mil.
ExpreS2ion Biotech Holding AB's average Total Assets over the quarter that ended in Mar. 2026 was €5.33 Mil. Therefore, ExpreS2ion Biotech Holding AB's annualized ROA % for the quarter that ended in Mar. 2026 was -66.78%.
The historical rank and industry rank for ExpreS2ion Biotech Holding AB's ROA % or its related term are showing as below:
FRA:5JD0'
s ROA % Range Over the Past 10 Years
Min: -88.1 Med: -53.24 Max: -32.44
Current: -54.68
During the past 13 years, ExpreS2ion Biotech Holding AB's highest ROA % was -32.44%. The lowest was -88.10%. And the median was -53.24%.
FRA:5JD0's ROA % is ranked worse than 66.55% of 1420
companies
in the Biotechnology industry
Industry Median: -32.87
vs FRA:5JD0: -54.68
ExpreS2ion Biotech Holding AB (FRA:5JD0) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
ExpreS2ion Biotech Holding AB ROA % Related Terms
ExpreS2ion Biotech Holding AB ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's ROA % distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a ROA % of -66.78% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on ExpreS2ion Biotech Holding AB and its competitors. According to the industry distribution chart, ExpreS2ion Biotech Holding AB ranks #945 out of 1420 companies in the Biotechnology industry, placing it in the top 66.5%.
Is ExpreS2ion Biotech Holding AB's ROA % too high?
ExpreS2ion Biotech Holding AB's current ROA % is -66.78%. Based on the distribution chart, ExpreS2ion Biotech Holding AB ranks #945 out of 1420 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ExpreS2ion Biotech Holding AB ranks #945 out of 1420 companies for ROA %. This places ExpreS2ion Biotech Holding AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current ROA % is -66.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a current ROA % of -66.78%. The stock's GF Value™ is €0.09, compared to a current price of €0.04 — trading 58.7% below its estimated fair value. The current ROA % is -66.78%. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (FRA:5JD0), the current ROA % is -66.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (FRA:5JD0) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued.
The current stock price of €0.04 is trading 58.7% below its estimated GF Value™ of €0.09.
Key valuation signals for FRA:5JD0:
ROA %: -66.78%
GF Value™: €0.09 vs. price of €0.04 (58.7% below fair value)
No single metric tells the full story. See the FRA:5JD0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB Business Description
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score
Get the complete analysis for FRA:5JD0
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5JD0 has been successfully added to your 
